Pharma Giants Limit TrumpRx Participation to 12% of Branded Drugs, Protecting Blockbusters

Behind the TrumpRx headlines lies a finely calibrated biopharma strategy. Faced with tariff threats and an administration demanding direct-to-consumer discounts, drugmakers signed cooperation agreements but then cherry-picked a token subset of drugs—92 out of over 800—to list on the government site. By excluding their biggest revenue drivers, including many biologic and oncology therapies, the industry preserved its pricing power while maintaining the appearance of compliance. For biotech and pharma executives, this episode offers a case study in navigating political pressure without sacrificing the high margins that fund R&D pipelines.

The Trump administration’s marquee drug pricing initiative, TrumpRx, has fallen dramatically short of its promise, according to an NPR analysis published six months after the website’s launch. Unveiled in February 2026, the direct-to-consumer discount portal currently lists just 92 deals on brand-name prescription drugs—a fraction of the over 800 brand-name medicines manufactured by the pharmaceutical companies that publicly agreed to participate. That 12% participation rate exposes a vast gulf between the White House’s rhetoric of a ‘supermarket’ for affordable medicines and the boutique reality. The 92 deals leave patients without discounts for entire therapeutic categories, including treatments for inflammatory conditions, HIV, and cancer, raising serious questions about the program’s ability to deliver meaningful savings for American families.

“

Independent pharmacists, who represent a critical distribution channel for generics (which account for 90% of U.S.

The origins of TrumpRx lie in a May 2025 executive order that aimed to bring U.S. drug prices in line with or below those of other wealthy countries. By the summer of 2025, the administration had sent letters to 17 major pharmaceutical companies listing demands that included selling drugs directly to consumers at lower prices—a model already pioneered by Eli Lilly and Novo Nordisk with their own direct-to-patient platforms. The letters carried an explicit threat: comply within 60 days or face ‘every tool in our arsenal,’ including tariffs resulting from an investigation into pharmaceutical imports. Behind closed doors, negotiators wielded this leverage, yet the outcome suggests that pharma companies, while willing to offer select discounts, drew a hard line at broad participation in what they likely viewed as a government-imposed price control mechanism.

The limited scope of TrumpRx is a calculated industry response. Dr. Ben Rome, a health policy researcher at Brigham and Women’s Hospital, told NPR that ‘most of these companies are doing this for a small number of products and in a limited setting,’ confirming that even the firms that signed cooperation agreements declined to engage at scale. By steering clear of their highest-revenue and medically critical drugs, the companies minimized both revenue erosion and the risk of international reference pricing impacts. This strategic submission allows them to point to cooperation while preserving the pricing power that sustains their blockbuster portfolios.